-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ST-266 in Trigeminal Neuralgia (Tic Douloureux)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ST-266 in Trigeminal Neuralgia (Tic Douloureux) Drug Details: ST-266 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-204 in Human Papillomavirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-204 in Human Papillomavirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-204 in Human Papillomavirus Infections Drug Details: MP-204 is under development...
-
Product Insights
Trigeminal Neuralgia (Tic Douloureux) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Trigeminal Neuralgia (Tic Douloureux) Clinical Trials Overview The Trigeminal Neuralgia (Tic Douloureux) clinical trial report consists of 129 trials. The report provides an overview of the Trigeminal Neuralgia (Tic Douloureux) clinical trials scenario. The report provides top-line data relating to the clinical trials on Trigeminal Neuralgia (Tic Douloureux). It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 &...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Myelofibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Myelofibrosis Drug Details: IMG-7289 is under development for the treatment of acute...
-
Product Insights
NewTourette Syndrome – Drugs In Development, 2024
Empower your strategies with our Tourette Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called "tics". Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms, and hopping. The predisposing factors include age and sex. Males are about three to four times more...
-
Product Insights
NewActinic (Solar) Keratosis – Drugs In Development, 2024
Empower your strategies with our Actinic (Solar) Keratosis – Drugs In Development, 2024 report and make more profitable business decisions. An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck, or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch...
-
Product Insights
NewChemotherapy Induced Neutropenia – Drugs In Development, 2024
Empower your strategies with our Chemotherapy Induced Neutropenia – Drugs In Development, 2024 report and make more profitable business decisions. Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain, dizziness, and abdominal pain. The predisposing factors include age, co-morbidities, and time course of therapy. The Chemotherapy Induced Neutropenia drugs in development market research report provide comprehensive information...
-
Product Insights
NewBasal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2024
Empower your strategies with our Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2024 report and make more profitable business decisions. Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include a waxy bump; a scaly, brown, or flesh-colored patch; or a white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery. The Basal Cell Carcinoma (Basal Cell Epithelioma) drugs in...
-
Product Insights
NewLeukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2024
Empower your strategies with our Leukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2024 report and make more profitable business decisions. Leukocyte disorders, also known as white blood cell disorders, encompass a range of conditions that involve abnormalities in the production, function, or levels of white blood cells (leukocytes). White blood cells play a crucial role in the immune system, defending the body against infections, diseases, and foreign invaders. The Leukocyte Disorders (White Blood Cell Disorders) drugs in development...
-
Product Insights
NewNonmelanomatous Skin Cancer – Drugs In Development, 2024
Empower your strategies with our Nonmelanomatous Skin Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Nonmelanoma skin cancer comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), originating from skin cells other than melanocytes. Linked to sun exposure, these cancers often appear on sun-exposed areas. BCC, the most prevalent, usually presents as a pearly bump or a sore that doesn't heal. SCC may appear as a scaly patch or a firm, red nodule. While rarely...